An Initial Low-Dose Etelcalcetide Dosing Strategy in Hemodialysis Patients With Moderate Secondary Hyperparathyroidism is Effective and Cost-Saving

Kidney Int Rep. 2023 Nov 15;9(2):482-485. doi: 10.1016/j.ekir.2023.11.009. eCollection 2024 Feb.

Andrea Carta^{1

2}, Martina Tedesco^{1

2}, Federica Mescia^{1

2}, Chiara Manenti¹, Bernardo Lucca¹, Federica Verzeletti¹, Alice Guerini^{1

2}, Federica Gaia Terni^{1

2}, Roberto Zubani^{1

2}, Simona Guerini¹, Brunella Valzorio¹, Guido Jeannin¹, Orsola Carli¹, Corrado Camerini³, Stefano Possenti¹, Paola Gaggia¹, Federico Alberici^{1

2}

¹ Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili of Brescia, Brescia, Italy.
² Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
³ Independent Researcher, Brescia, Italy.

No abstract available

Keywords: CKD-MBD; PTH; calcimimetics; etelcalcetide; hemodialysis; secondary hyperparathyroidism.